iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** X **Month of publication:** October 2025

DOI: https://doi.org/10.22214/ijraset.2025.74840

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue X Oct 2025- Available at www.ijraset.com

Introduction to Adverse Effects of Chemotherapy Agent

Sonal Navnath Dhotre[1], Snehal Suresh Pise[2], Harshad Awate[3], Prachi Mahendra Bhosale[4]
Mandesh Institute of Pharmaceutical Sciences and Research Centre Mhaswad

Abstract: Chemotherapy remains a cornerstone in modern cancer management, yet its administration is frequently accompanied by diverse side effects that can undermine both patient wellbeing and adherence to prescribed regimens. This review synthesizes evidence on the primary and most impactful adverse events linkedto chemotherapy agents, exploring the biological mechanisms behind them and outlining contemporary managementapproaches.
Athoroughanalysis ofpublishedclinicalstudiesunderscorestheimportanceoftailoring supportive care strategies to each individual in order to limit toxicity and improve overall outcomes.

I. INTRODUCTION

Cancer represents a group of disorders defined by unregulated cellular proliferation within bodily tissues or organs. Treatment strategies depend on variables including cancer site, stage, and cellular characteristics.Notably, cancer holdsthedistinction ofbeingtheworld'ssecondmost common causeofdeath.

Alongsidesurgeryandradiotherapy,chemotherapyisapivotaltherapeuticavenue.Advancesinpharmaceutical research are continually generating novel anticancer drugs, yet these agents impact both psychological and physical health, manifesting as pain, insomnia gastrointestinal distress, emotional disturbances, and more.

Increasingawarenessofcancerasachronichealthconditionhasledtorecognitionofself-managementand individualized care as essential elements in long-term treatment planning.

A. Types of cancers:

Overonehundreddistinctcancersaffecthumans,arisingfromvarioustissueorigins.They are commonly categorized as follows:

1) Carcinomas:Originatefromepithelialtissues,accountingformostbreast,lung,prostate,andcoloncancers. Sarcomas: Develop from connective tissues such as bone, muscle, or fat.
2) Leukemias:Arise in hematopoietic (blood-forming) tissues, leading to abnormal proliferation of blood cells.
3) LymphomasandMyelomas:Originatefromcellsoftheimmunesystem,affectinglymphnodesandplasmacells.
4) CentralNervousSystemTumours:Includemalignanciesofthebrainandspinalcordsuchasgliomasand medulloblastomas.
5) GermCellTumors:Emergefromreproductivecells,oftenaffectingtheovariesortestes.
6) Blastoma:Derivedfromimmaturecellsorembryonictissue,morecommoninpediatricpopulations(e.g.,neuroblastoma,retinoblastoma).Frequentlyoccurringcancertypesbyorganorsystemincludebreast,lung,colorectal,bladder,andskincancers, as well as various leukemias and lymphomas.

B. Classification of Chemotherapy Agent

Chemotherapydrugsarecentraltosystemiccancertherapyand are classified by their molecular structure and activity in targeting malignant cells. Major classes include

1) AlkylatingAgents: These compounds damage DNAby introducing alkyl groups, causing breaks in DNA strandsandultimatelyinhibitingcellreplication.Commonagentsincludecyclophosphamideandifosfamide.
2) Mechanism:AlkylatingagentscreatehighlyreactivecarboniumionsthatbindcovalentlytoDNA,prompting cross-linking, base mispairing, and strand breaks, which together halt DNAsynthesis and cell division.
3) Antimetabolites:ThesedrugsmimicnaturalmoleculesnecessaryforDNAandRNAsynthesis,thereby interrupting genetic material formation in rapidlyproliferating cells. Examples include methotrexate and fluorouracil.
4) Anti-TumorAntibiotics:Distinctfromantibacterialagents,thisgroupinterfereswithDNAreplicationby directly binding to DNA; doxorubicin and bleomycin are key representatives.
5) TopoisomeraseInhibitors:ThesedisruptenzymesrequiredforDNAstrandunwinding,preventingcelldivision. Drugs like etoposide and irinotecan are in this category.

6) MitoticInhibitors(PlantDerivatives):Derivedfromnaturalsources,theseagents(e.g.,vincristine,paclitaxel) interfere with microtubule function, blocking cell division.

7) Corticosteroids:Sometimesincludedinchemotherapyregimenstominimizeinflammationandimmune responses, corticosteroids also help manage treatment side effects.

Eachclassutilizesauniquemechanismtoselectivelytargetneoplasticcellsbutcanalsoimpactnormalrapidly dividing cells, accounting for the broad spectrum of side effects encountered during chemotherapy.

II. CHEMOTHERAPY AGENT ADVERSE EFFECTS WITH ITS MECHANISMOFACTION

A. Alkylatingagent: Adverse Effects and Mechanistic Basis

Class Effects- Bone marrow suppression (most common and dose-limiting)Gastrointestinal distress (nausea, vomiting,mucositis)AlopeciaSecondarymalignancies (notablyAML, duetomutagenic effects)Organ-specific toxicitiesdependingonthedrug:Cyclophosphamide→bladder,Busulfan→lungs,skin,Nitrosoureas→CNS Dacarbazine → liver and marrow

Quick Mnemonic for Distinct Toxicities - Cyclophosphamide→Cystitis(fromacrolein) Busulfan → Breathless (lung fibrosis) Nitrosoureas→ Neural toxicity

Procarbazine→Peculiarreactions(disulfiram-like)

Drug	MajorAdverseEffects&Rationale	Mechanismof Toxicity
Carmustine/Lomustine (Nitrosoureas)	Myelosuppression-Hemorrhagic cystitis(acroleinbyproduct)-SIADH (rare)-Secondarymalignancies (e.g., leukemia,bladdercancer)	FormDNA crosslinks, especiallyin rapidlydividing cells;toxic metabolites
		(acrolein) cause additionaltissue irritation.
Busulfan	Profound myelosuppression-Pulmonaryfibrosis(“busulfanlung”)- Skin hyperpigmentation (“busulfan tan”)-Adrenal insufficiency (rare)	Causes alkylation and cross-linking ofDNA,impairing replication in hematopoieticand epithelial tissues.
Carmustine/Lomustine (Nitrosoureas)	CNS toxicity (ataxia, seizures, confusion)-Bonemarrowsuppression (delayed)-Pulmonary fibrosis (rare)	Cross the blood– brain barrier and formDNA–protein crosslinksinneural andtumortissues.
Dacarbazine/ Procarbazine	Myelosuppression-Nausea and vomiting-Leukemogenicpotential- Disulfiram-like reaction and MAO inhibition (esp. procarbazine)	Methylatingagents that damage DNA through free radicals and alkylation.
Melphalan/Chlorambucil	Myelosuppression-Secondary leukemia (long-term use)-GI irritation	Classic alkylators binding DNA guanineresidues→ impaired replication.

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue X Oct 2025- Available at www.ijraset.com

B. Antimetabolites–AdverseEffects

Drug	MajorAdverseEffects&Rationale	MechanismofToxicity
Methotrexate(MTX)(Folate antagonist)	Bonemarrowdepression(↓WBCs, RBCs, platelets)-Mouth ulcers (mucositis)-Liverinjury(↑LFTs, long-term fibrosis risk)-Rarely, pulmonary fibrosis	Blocks dihydrofolate reductase, suppressing DNA synthesis in rapidlydividingtissues such as bone marrow, mucosal lining, and hepatic cells.
5-Fluorouracil(5-FU) (Pyrimidine analog)	Myelosuppression-Hand–foot syndrome(pain,redness,peeling on palms/soles)-Diarrhea, mucositis-Photosensitivity	Converted to FdUMP, inhibiting thymidylate synthase→faultyDNA formation → destruction of tissues withhighcell turnover.
Cytarabine (Ara-C) (Pyrimidineanalog)	Severe pancytopenia-GI irritation (nausea, vomiting, diarrhea)-Neurotoxicity(ataxia, slurred speech, esp. high doses/elderly)-Conjunctivitis	IncorporatedintoDNA; blocks DNApolymeraseanddisrupts synthesis in proliferating cells.
Gemcitabine(Pyrimidine analog)	Bonemarrowsuppression-Flu- like syndrome-Rare interstitial lung injury	Acts as a chain terminatorduringDNA replication, damaging proliferating marrow and pulmonary cells.
6-Mercaptopurine(6-MP) (Purine analog)	Myelosuppression-Hepatic damage	Converted by HGPRT; interferes with purine synthesis → toxic to hematopoieticandliver cells.

C. Anti-tumoragent–Adverseeffects:

Drug	MajorAdverseEffects&Rationale	MechanismofToxicity
VincaAlkaloids(Vincristine, Vinblastine)	Neurotoxicity (peripheral neuropathy, more common with vincristine)-Myelosuppression (vinblastine)-Constipation (autonomicneuropathy)	Disrupt microtubule formation,impairingmitosis.
Taxanes(Paclitaxel, Docetaxel)	Neutropenia-Peripheral neuropathy-Hypersensitivityreactions (particularly paclitaxel)	Stabilize microtubules preventingdisassembly, hindering mitosis.

Anthracyclines(Doxorubicin, Daunorubicin)	Cardiotoxicity (dose- dependent congestive heart failure)-Myelosuppression -Alopecia-Mucositis	Intercalate into DNA, generatefreeradicalscausing oxidative damage.
Bleomycin	Pulmonary fibrosis (main concern)-Skin hyperpigmentation-Minimalmyelosuppression	InducesDNAstrandbreaks via free-radical formation.

D. TopoisomeraseInhibitors–AdverseEffects

Drug/Class	MajorAdverseEffects& Rationale	MechanismofToxicity
Etoposide / Teniposide (TopoisomeraseII inhibitors)	Myelosuppression (especially leukopenia)-Alopecia-Mucositis and GI irritation-Secondary acute leukemia (typically after prolonged use)	Block topoisomerase II, preventingre-ligationofDNA strands → accumulation of double-strand breaks → cell death in dividing cells.
Topotecan/ Irinotecan (TopoisomeraseI	Severe diarrhea (early form due to cholinergiceffects;lateformdueto mucosaldamage)-Neutropenia	InhibittopoisomeraseI,resulting insingle-strandDNAbreaksthat impairreplicationand
inhibitors)	(dose-limiting)-Nausea and vomiting-Fatigueandweakness	transcription.

E. MitoticInhibitors(Plant-DerivedAgents)–AdverseEffects

Drug	MajorAdverseeffects&rationale	MechanismofToxicity
VincaAlkaloids(Vincristine, Vinblastine, Vinorelbine)	Vincristine – Peripheral neuropathy (sensory + motor), constipation,jawpain,SIADH; minimal marrow toxicity.- Vinblastine / Vinorelbine – Myelosuppression (dose-limiting),mucositis,mild neurotoxicity.	Bind to β-tubulin and prevent microtubule polymerization→haltcell division at metaphase.
Taxanes (Paclitaxel, Docetaxel,Cabazitaxel)	Myelosuppression (mainlimiting factor)-Peripheral neuropathy-Hypersensitivity reactions (from solvent; reduced withnewerformulations)-Nail and hair changes (alopecia, nail discoloration)-Fluid retention, especiallywith docetaxel	Stabilizemicrotubules, preventing their depolymerization → mitotic arrest in metaphase.
Podophyllotoxins(Etoposide, Teniposide)	Myelosuppression-Mucositis -Secondary leukemia (rare, relatedtoDNAdamage)-Hair loss	Inhibit topoisomerase II and interfere with microtubule dynamics (technicallyoverlapswith topoisomeraseinhibitors).

III. EFFECTS METHODS OF IDENTIFICATION OF ADVERSEEFFECTS

1) ClinicalTrials and Pharmacovigilance:During clinicaltrials, adverse effects are meticulouslyrecorded and classified using scales like the Common Terminology Criteria forAdverse Events (CTCAE)bythe NationalCancerInstitute.Post-marketingsurveillanceidentifiesrareandlong-termeffectsnotobserved intrials.

2) Patient-ReportedOutcomes(PROs):ToolslikethePatient-ReportedOutcomesMeasurementInformation System (PROMIS) enable patients to self-report symptoms, offering real-world insights.
3) BiomarkersandImaging:Biochemicalmarkers(e.g.,liverenzymesforhepatotoxicity)andimaging Techniques (e.g., echocardiography for cardiotoxicity) help identify subclinical damage.
4) HealthcareProviderMonitoring:Regularassessmentofhematological,hepatic,renal,andcardiac functions provides objective data on drug-indused organ damage.

IV. FORMULATION STRATEGIES TO REDUCE ADVERSE EFFECTS OF CHEMO THERAPY DRUGS

Drug	Formulation method	Formulation type	Typeofcancer	Reducedadverse effects	Biomarker	Outcome
Doxorubicin	Surface PEGylation and lipid vesicle entrapment	PEG-Liposomal (Doxil)	Ovarian, Kaposi's sarcoma, Multiple myeloma	Loweredcardiac damage and bone marrow suppression	Folate receptor expression	Extended circulation andtargeted drug accumulation
Daunorubicin	Lipid bilayer encapsulation	Liposomal (DaunoXome)	Kaposi's sarcoma	Reduced systemic cytotoxicity	Enhanced permeability andretention (EPR)	Improved tolerability and drug retention
Irinotecan	PEG-lipid vesicle composition	PEG-Liposomal (Onivyde)	Pancreatic carcinoma	Less gastrointestinal irritation	TumorEPR mechanism	Prolonged drug availability and improved overall survival
Paclitaxel	Albumin-based nanoparticle conjugation	Albumin- bound particles (Abraxane)	Breast,Lung, Pancreatic	Avoidance of solvent-induced allergies	SPARC-binding protein	Enhanced absorption and reduced hypersensitivity
Cytarabine	Controlled-releaselipid suspension	Liposomal (DepoCyt)	Lymphomatous meningitis	Decreased neurotoxic events	CSF-residing malignant cells	Sustained CSF concentrationwithf ewer hospital visits
Vincristine	Phospholipid-encapsulated vesicle	Liposomal (Marqibo)	Acute lymphoblastic leukemia	Diminished neurotoxicity	CD44 ligand- mediated targeting	Increased stabilityand therapeutic activity
Docetaxel	Amphiphilic polymer micellization	PEG-PDLLA micelle system	Lungandbreast carcinomas	Lower hypersensitivity, reducedsystemic damage	Tubulin affinityand HSP90 linkage	Slow release andimproved intracellular accumulation
Cisplatin	PEG-stabilized lipid vesicle	PEG-Liposomal (Lipoplatin)	Lung,Breast, Gastric	Reducedrenal and auditory toxicity	Transferrin receptor targeting	Enhanced tumor selectivity

						andsafety margin
Doxorubicin (Folate- targeted)	Ligand-based nanocarrier	Folate-linked liposomalNP	Cervical,Breast	Decreasednon- specific distribution	Folate receptorα	Greater tumor selectivity and attenuated off-target reactivity
Paclitaxel (HA-targeted)	Hyaluronic acid-modified nanoparticle	HA-Liposomal system	Breast, Colorectal	Loweralopecia and systemic exposure	CD44 receptor	Improved therapeutic index and patient outcome

Summary of strategies – Liposomal drug carriers modify biodistribution and exploit the enhanced permeability andretention (EPR)effect, therebylowering systemic toxicity; notable examplesincludeDoxiland DaunoXome. Polymeric micelles enhance the stability of poorly soluble drugs such as docetaxel and enable controlled release, contributing to reduced adverse effects.Albumin-bound nanoparticle systems, likeAbraxane, improve drug Solubilityandreducehypersensitivitylinkedtoorganicsolvents.Activetargetingnanocarriersutilizeligandssuch as folate, transferrin, or hyaluronic acid to enhance tumor-specific accumulation while minimizing off-target interactions. Biomimetic nanostructures, incorporating cancer cell membranes, promote immune evasion and improved biocompatibility.Altogether, these innovative formulations highlight the importance of nanocarrier design, surface engineering, and targeted delivery strategies in lowering chemotherapy-induced toxicity without compromising therapeutic efficiency.

V. MANAGEMENT AND MITIGATION STRATEGIES

1) PreventiveMeasures:Antiemetics(e.g.,Ondansetron). Pre-treatment hydration for nephrotoxicity.
2) SupportiveCare:Growthfactors(e.g.,Filgrastimforneutropenia). 3.Lifestyle Adjustments: Diet, exercise, and psychological support.

VI. FUTURE PROSPECTIVE

1) AdvancesinIdentification:NoveldrugdesignslikeDRP-104,whichareactivatedspecificallyintumor tissues but not in normal tissues, aim to reduce side effects by targeting delivery and activation mechanisms, thus minimizing damage to healthy cells .Scoring systems such as the Cardiotoxicity Score (CardTox-Score) have been developed to predict chemotherapy-induced myocardial toxicity using clinical, biochemical, and echocardiographic data, enabling proactive risk assessment before therapy .Longitudinal approaches like the Multiple Overall Toxicity(MOTox)scoreevaluatetoxicitycycle-by-cycleduringchemotherapy,whichcaninformtimely interventions to manage cumulative adverse effects .
2) Research and Monitoring : Hospital-based pharmacovigilance and monitoring of adverse drug reactions (ADRs)byclinicalpharmacistsimproveearlydetectionandreporting,whichreduceshealthandeconomic burdens associated with chemotherapy toxicity .There is ongoing emphasis on understanding and controlling specific side effects such as delayed nausea and vomiting by studying molecular pathways involved, leading to better antiemetic therapies .
3) Future Trends :Integration of predictive models using patient-specific data to tailor chemotherapy regimensminimizingadverseeffectsisanemergingtrend,asseenwithmodelspredictinghaematological toxicity in lung cancer . Advancesinunderstandingsystemicbystandereffectscausedbychemotherapy-inducedDNAdamageand inflammation may lead to new preventive measures .Enhanced patient self-reporting and real-world data collection on adverse effects will contribute to refined risk models and personalized management strategies. Overall, the future holds promise in combining precision medicine, predictive analytics, novel drug formulations, and comprehensive monitoring platforms to better identify and mitigate chemotherapy adverse effects, improving patient outcomesandqualityof life.

VII. APPLICATION

1) Clinical Applications: Hospital and Infusion Center SettingsModern chemotherapy formulations like Doxil(PEG-liposomaldoxorubicin)andAbraxane(albumin-boundpaclitaxel)areadministeredinclinical oncology units where patients receive targeted infusions with reduced monitoring requirements due to their improved safety profiles .

- Personalized Medicine Implementation : These formulations enable biomarker-driven treatment selection,whereoncologistsusemoleculartestingtoidentifypatientswithfolatereceptoroverexpression, SPARCproteinlevels,orCD44expressiontooptimizedrugselectionandimprovetherapeuticoutcomes.
- Combination Therapy Protocols :The reformulated drugs facilitate multi-agent chemotherapy regimens with improved tolerability. For example, GEM/DOX liposome combinations have demonstrated superior survivaloutcomescomparedtosingle-agenttreatments,extendingmediansurvivalby3.4timescompared to controls .
- OutpatientTreatmentExpansion:Enhancedsafetyprofilesallowforambulatorycaredelivery,reducing hospitalization requirements and enabling patients to receive treatment in outpatient settings with fewer side effect-related complications • Pediatric and Geriatric Oncology :Reduced toxicity formulations are particularly valuable in vulnerable populations where traditional chemotherapy doses must be limited.
  Liposomalvincristine(Marqibo)exemplifiesthisapplicationinpediatricacutelymphoblasticleukemia.

2) Therapeutic Applications

- Tumor-Specific Targeting:Advanced formulations exploit the enhanced permeability and retention (EPR)effectinsolidtumor,allowingpreferentialdrugaccumulationincanceroustissueswhilesparing healthy organs .
- ControlledDrugRelease:Sustained-releaseformulationsmaintaintherapeuticdrugconcentrationsover extended periods, reducing dosing frequency and improving patient compliance while minimizing peak- related toxicity .
- Overcoming Drug Resistance : Nanoparticle systems can bypass multidrug resistance mechanisms by altering cellular uptake pathways and drug efflux patterns, potentially restoring sensitivity to previously ineffective agents.•Microenvironment-Responsive Delivery : Intelligent delivery systems respond to tumor-specific conditions such as acidic pH or elevated lactate levels (up to 40-fold higher than normal tissue), enablingprecisedrugreleaseatthetargetsite. •ImmunogenicCellDeathEnhancement:Certain formulations promote immunogenic cell death, recruiting immune cells to tumor sites and potentially enhancing the body's natural anti-cancer response beyond direct cytotoxic effects .

REFERENCES

[1] A.Foitz,G.Gaines,M.GullotteeRecalledsideeffectsandself-careactionofpatientreceiving.
[2] Inpatientchemotherapy,medicaloncologyunitAmericanjournal,23(4)(2015)1996;23
[3] L.A.Torre,F.Bray,R.L.Siegel,etal.GlobalcancerstatisticsCACancerJClin,65(2)(2012),pp.87- 1082015
[4] Cancer statistics Facts and figures (Internet) . Cited on 2018.Available Fromhttp://www.cancer.org/latest-news/facts-and-figures-2018-rateof-deaths-fromcancercontinues-decline.html (2018), Accessed 20th Apr 2020
[5] NationalCancerInstituteChemotherpy(Internet),(Cited2010Jan18),AvailableFrom http://www.nci.go.th/knowledge/chem.htm (2010)Google Scholar
[6] B.A.Chabner,T.G.RobertsTimeLine:chemotherapyandthewaroncancerNatRevCanc,5(1) (2005), pp. 65-72, 10.1038/nrc1529PMID:15630416Accessed 19th May 2020
[7] F.T.Arslan,KantarM.BasbakkalZQualityoflifeandchemotherapy–realtedsymptomsofTurkish cancer children undergoingchemotherapyAsian Pac J Cancer prevention, 14 (2013),pp. 1761-1768
[8] DHowell,DKMayer,RFielding,MEicher,IMVerdonck-deLeeuw,CJohansen,Al.Managementof CancerandHealthAftertheClinicVisit:ACalltoActionforSelfManagementinCancerCareJNCIJ Natl Cancer Inst, 113 (5) (2020 May 4)
[9] J.Barlow,C.Wright,J.Sheasby,A.Turner,J.HainsworthSelf-managementapproachesforPeople with chronic conditions: a review Patient Educ Counsel, 48 (2) (2002), pp. 177-187
[10] FDA.(2023).ClinicalTrialGuidelinesforChemotherapySafetyMonitoring.
[11] WorldHealthOrganization(WHO).(2021).Pharmacovigilance:EnsuringSafeDrugUse.
[12] NationalCancerInstitute.(2023).CommonTerminologyCriteriaforAdverseEventsv5.0.Retrieved from cancer.gov.
[13] Naranjo,C.A.,etal.(1981).AMethodforEstimatingtheProbabilityofAdverseDrugReactions. Clinical Pharmacology & Therapeutics.
[14] Chabner,B.A.,&Longo,D.L.(2011).CancerChemotherapyandBiotherapy:PrinciplesandPractice. Lippincott Williams & Wilkins
[15] DeVita,V.T.,Lawrence,T.S.,&Rosenberg,S.A.(2015).Cancer:Principles&PracticeofOncology. Wolters Kluwer
[16] Katzung,B.G.,&Trevor,A.J.(2018).BasicandClinicalPharmacology.McGraw-HillEducation.
[17] Alberts,D.S.,&Hess,L.M.(2004).FundamentalsofCancerPrevention.Springer
[18] .Clarke,R.,&Brünner,N.(2004).HormonalTherapyinCancer.CancerResearch.
[19] Hanahan,D.,&Weinberg,R.A.(2011).HallmarksofCancer:TheNextGeneration.Cell.
[20] Mellman,I.,Coukos,G.,&Dranoff,G.(2011).CancerImmunotherapyComesofAge.Nature.

[21] Chabner,B.A.,&Longo,D.L.(2016).CancerChemotherapyandBiotherapy:Principlesand Practice.
[22] Gupta,S.,etal.(2021).Organ-SpecificToxicitiesofChemotherapyDrugs.EuropeanJournalOf Cancer.
[23] Lyman,G.H.(2020).SecondaryMalignanciesinCancerSurvivors.JournalofClinicalOncology.
[24] .Harrison,M.(2019).Long-TermEffectsofCancerTreatment.SurvivorshipResearchReview.
[25] Jones,T.,etal.(2018).Chemotherapy-InducedMyelosuppression.HematologyToday.
[26] .Patel,R.,etal.(2022).MolecularMechanismsofChemotherapyToxicity.SpringerNature.
[27] FDA(2023).ChemotherapyDrugGuidelines.Retrievedfromfda.gov.
[28] WorldHealthOrganization(2022).CancerTreatmentComplications.WHOInternationalDatabase.
[29] .Kumar,P.,etal.(2021).OxidativeStressinChemotherapy-InducedToxicity.FreeRadicalResearch.
[30] Jain,S.,etal.(2021).CardiotoxicityofAnthracyclines.Cardio-OncologyReview.
[31] AmericanCancerSociety(2023).KidneyToxicityofPlatinum-BasedDrugs.Retrievedfrom Cancer.org.
[32] Springer,M.(2020).PeripheralNeuropathyinTaxaneTherapy.JournalofPainManagement.
[33] WHO(2022).HepatotoxicityfromChemotherapyDrugs.WHOGuidelinesonCancerManagement.
[34] Lyman,G.H.(2021).UseofG-CSFsinChemotherapyManagement.Haematology&Oncology.
[35] NIHClinicalTrialsDatabase(2023).EmergingTherapiestoReduceChemotherapyToxicity.Retrieved from nih.gov
[36] Smith,T.,etal.(2020).LiposomalDrugFormulationsinCancerTherapy.DrugDeliveryInnovations.
[37] MayoClinic(2023).PersonalizedApproachesinChemotherapy.RetrievedfromMayoclinic.org.
[38] EuropeanJournalofCancer(2022).BiomarkersforPredictingChemotherapyResponse.Research Update.
[39] Harrison,M.,etal.(2017).SecondaryCancersAfterChemotherapy.OncologySurvivorshipStudies.



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY